Longitudinal Changes in Ki-67 Indices in Small-Intestinal Neuroendocrine Tumours and Their Impact on Survival.

IF 4.3 3区 材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC
Kosmas Daskalakis, Marina Tsoli, Maria Wedin, Beata Kos-Kudla, Angelika Kogut, Raj Srirajaskanthan, Dominique S V M Clement, Georgios Giovos, Martin O Weickert, Gregory Kaltsas
{"title":"Longitudinal Changes in Ki-67 Indices in Small-Intestinal Neuroendocrine Tumours and Their Impact on Survival.","authors":"Kosmas Daskalakis, Marina Tsoli, Maria Wedin, Beata Kos-Kudla, Angelika Kogut, Raj Srirajaskanthan, Dominique S V M Clement, Georgios Giovos, Martin O Weickert, Gregory Kaltsas","doi":"10.1159/000541101","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of this study was to evaluate longitudinal changes in Ki-67 indices of SI-NETs and assess the impact of these in overall survival (OS).</p><p><strong>Methods: </strong>We screened 551 patients with SI-NETs diagnosed from 1993, through 2021, identified using the SI-NET databases from five European referral centres. Only patients with well-differentiated tumours and available baseline tumour samples and follow-up re-biopsies were included. For tumour grading, apart from 2017 WHO classification system, we applied a recently proposed SI-NET site-specific modified histopathological grading system with Ki-67 cut-offs of 5 and 10%. Uni- and multivariable regression analyses were used to determine whether there was a difference between OS in SI-NET patients stratified by increment of Ki-67 indices over time and/or progression to a higher grade.</p><p><strong>Results: </strong>We included 45 patients. Median Ki-67 index at SI-NET diagnosis was 2% (range: 0.5-15%). Thirty-three patients had Ki-67 indices &lt;5% (70.2%), 6 had Ki-67: 5-10% (12.8%), and 8 had Ki-67 ≥10% (17%). Mean time to re-biopsy was 48.8 months (SD: ±162.5). At re-biopsy, the median change in Ki-67 index (absolute value; follow-up minus time of diagnosis) was 1% (range: -10 to +38%). An increase in Ki-67 occurred in 20 patients (42.6%); in 14 patients, the change in Ki-67 resulted in progression to higher tumour grade following the modified grading system. Patients with an increment in Ki-67 ≥1% had a median OS of 32.9 months versus 80.5 months in patients without (HR = 5.6, 95% CI: 1.42-22.02; p = 0.014). When applying the novel modified histopathological grading system for SI-NETs, patients with grade progression had a median OS of 32.9 months versus 53.7 months in those without (HR = 4.61, 95% CI: 1.22-13.54; p = 0.022). At multivariable analysis, grade progression was confirmed as an independent predictor for death (HR = 7.2, 95% CI: 1.58-32.82; p = 0.011).</p><p><strong>Conclusions: </strong>Metachronous increment in Ki-67 indices and related grade progression over time following a site-specific modified histopathological grading system with Ki-67 cut-offs of 5 and 10% is observed in approximately 1/3 of SI-NETs subjected to re-biopsy and it is associated with worse survival outcomes.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000541101","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The purpose of this study was to evaluate longitudinal changes in Ki-67 indices of SI-NETs and assess the impact of these in overall survival (OS).

Methods: We screened 551 patients with SI-NETs diagnosed from 1993, through 2021, identified using the SI-NET databases from five European referral centres. Only patients with well-differentiated tumours and available baseline tumour samples and follow-up re-biopsies were included. For tumour grading, apart from 2017 WHO classification system, we applied a recently proposed SI-NET site-specific modified histopathological grading system with Ki-67 cut-offs of 5 and 10%. Uni- and multivariable regression analyses were used to determine whether there was a difference between OS in SI-NET patients stratified by increment of Ki-67 indices over time and/or progression to a higher grade.

Results: We included 45 patients. Median Ki-67 index at SI-NET diagnosis was 2% (range: 0.5-15%). Thirty-three patients had Ki-67 indices <5% (70.2%), 6 had Ki-67: 5-10% (12.8%), and 8 had Ki-67 ≥10% (17%). Mean time to re-biopsy was 48.8 months (SD: ±162.5). At re-biopsy, the median change in Ki-67 index (absolute value; follow-up minus time of diagnosis) was 1% (range: -10 to +38%). An increase in Ki-67 occurred in 20 patients (42.6%); in 14 patients, the change in Ki-67 resulted in progression to higher tumour grade following the modified grading system. Patients with an increment in Ki-67 ≥1% had a median OS of 32.9 months versus 80.5 months in patients without (HR = 5.6, 95% CI: 1.42-22.02; p = 0.014). When applying the novel modified histopathological grading system for SI-NETs, patients with grade progression had a median OS of 32.9 months versus 53.7 months in those without (HR = 4.61, 95% CI: 1.22-13.54; p = 0.022). At multivariable analysis, grade progression was confirmed as an independent predictor for death (HR = 7.2, 95% CI: 1.58-32.82; p = 0.011).

Conclusions: Metachronous increment in Ki-67 indices and related grade progression over time following a site-specific modified histopathological grading system with Ki-67 cut-offs of 5 and 10% is observed in approximately 1/3 of SI-NETs subjected to re-biopsy and it is associated with worse survival outcomes.

小肠神经内分泌肿瘤 Ki-67 指数的纵向变化及其对生存期的影响
简介:本研究旨在评估SI-NET的Ki-67指数的纵向变化,并评估这些变化对总生存率(OS)的影响:本研究旨在评估SI-NET的Ki-67指数的纵向变化,并评估这些变化对总生存率(OS)的影响:我们筛选了从1993年到2021年确诊的551例SI-NET患者,这些患者是通过欧洲5个转诊中心的SI-NET数据库确定的。只有肿瘤分化良好、有基线肿瘤样本和随访再活检样本的患者才被纳入。在肿瘤分级方面,除2017年世界卫生组织分类系统外,我们还采用了最近提出的SI-NET特定部位改良组织病理学分级系统,Ki-67临界值分别为5%和10%:我们共纳入了45名患者。SI-NET诊断时的Ki-67指数中位数为2%(范围为0.5-15%)。33例患者的Ki67指数为5%(70.2%),6例患者的Ki67指数为5%-10%(12.8%),8例患者的Ki67指数≥10%(17%)。再次活组织检查的平均时间为48.8个月(SD:+/-162.5)。再次活组织检查时,Ki-67指数(绝对值;随访时间减去诊断时间)的中位数变化为1%(范围为-10%至+38%)。20名患者(42.6%)的Ki-67指数出现了上升;14名患者的Ki-67指数变化导致其肿瘤分级升高(根据修改后的分级系统)。Ki-67增高≥1%的患者的中位OS为32.9个月,而未增高的患者为80.5个月(HR 5.6,95% CI:1.42-22.02,P=0.014)。当采用新的改良组织病理学分级系统对SI-NETs进行分级时,分级进展患者的中位OS为32.9个月,而未分级进展患者的中位OS为53.7个月(HR=4.61,95%CI:1.22-13.54;P=0.022)。多变量分析证实,分级进展是死亡的独立预测因素(HR=7.2,95%CI:1.58-32.82;P=0.011):本研究中约有1/3的SI-NET观察到Ki-67指数随着时间的推移而同步增加,相关的分级也随之进展,Ki-67的临界值为5%和10%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.20
自引率
4.30%
发文量
567
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信